A Phase 2 interventional study of Prizloncabtagene Autoleucel in Large B Cell Lymphoma, LBCL and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by AbelZeta Inc.. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by AbelZeta Inc. · Phase 2, Interventional, and Treatment
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy
Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.
1,432 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's planned enrollment of 55 is above the median of 47 across 1,214 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →AbelZeta Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Diagnosis of B-cell non-Hodgkin lymphoma (B-NHL), including the following neoplasms as defined by the 2022 WHO classification of lymphoid neoplasms:
Key Exclusion Criteria:
Participants will receive: • Leukapheresis • Fludarabine • Cyclophosphamide • Single intravenous infusion of Prizlon-cel.
Biological: Prizloncabtagene Autoleucel
An Autologous anti-CD19/CD20 chimeric antigen receptor T-cell therapy
Overall Response Rate (ORR)
ORR, including CR rate and PR rate according to the Lugano Criteria 2014
Time frame: Through Month 24
Incidence and severity of adverse events (AEs)
Evaluate the incidence, severity, and relationship of adverse events following C-CAR168 infusion, graded according to NCI CTCAE Version 6.0.
Time frame: Through Month 24
Duration of Response (DOR)
Duration of response from first objective response
Time frame: Through Month 24
Complete Response Rate
Percentage of participants that received Prizlon-cel that achieve a complete response
Time frame: Through Month 24
Best Overall Response (BOR)
Best overall response of participants that received Prizlon-cel
Time frame: Through Month 24
Time to Response
Time of first objective response from Prizlon-cel infusion
Time frame: Through Month 24
Progression Free Survival (PFS)
Time from enrollment until progression, relapse or death
Time frame: Through Month 24
Overall Survival (OS)
Time from date of enrollment to the date of death from any cause.
Time frame: Through Month 24
Quantitative polymerase chain reaction (qPCR) to determine maximum plasma concentration of Prizloncel post infusion
Characterize CAR T-cell expansion and persistence using qPCR to measure maximum plasma concentration (Cmax) after Prizloncel infusion
Time frame: Through Month 24
Area under the Curve (AUC) utilizing flow cytometry to determine Prizloncel persistence
Characterize T-cell expansion and persistence utilizing flow cytometry to determine the AUC of Prizloncel in peripheral blood
Time frame: Through Month 24
Changes in CD19/CD20-positive cells in peripheral blood after Prizlon-cel infusion
Changes in CD19/CD20-positive cells in peripheral blood after Prizlon-cel infusion utilizing flow cytometry
Time frame: Through Month 24
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prizloncabtagene autoleucel
Lymphoma, Large B-Cell, Diffuse →